Navigation Links
OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
Date:5/30/2009

with OGX-011 in metastatic castrate resistant prostate cancer, subject to the receipt of additional funding. The U.S. Food & Drug Administration (FDA) has agreed on the design of two Phase 3 registration trials, via the Special Protocol Assessment (SPA) process, of OGX-011 in combination with second-line chemotherapy. One trial design investigates overall survival as the primary endpoint; the other trial design investigates pain palliation as the primary endpoint. Based on the survival benefit observed after combining OGX-011 with first-line docetaxel chemotherapy, OncoGenex has initiated discussions with the FDA regarding evaluating the overall survival benefit in patients treated with first-line chemotherapy, rather than second-line chemotherapy.

OGX-011 has received Fast Track designation from the FDA for the treatment of progressive metastatic prostate cancer in combination with docetaxel.

About OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate currently completing five Phase 2 clinical trials in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase 1 clinical development; SN2310 has completed the Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development.

OGX-011, OGX-427 and OGX-225 utilize second-generation antisense technology, licensed from Isis Pharmaceuticals (NASDAQ: ISIS), to effectively target and inhibit production of specific proteins in tumor cells. OncoGen
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
2. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
3. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
4. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
5. OncoGenex Reports First Quarter Financial Results
6. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
7. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
8. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
9. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
10. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
11. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... one of the most promising technologies for future quantum ... (photons) instead of electrons. First, it is necessary to ... and control their direction. Researchers around the world have ... but now scientists at the Niels Bohr Institute have ... one at a time and in a particular direction. ...
(Date:8/29/2014)... Albany, New York (PRWEB) August 29, 2014 ... Research “Global Orthobiologics Market” the global orthobiologics market was valued ... reach a market worth USD 5,519.9million in 2019at a CAGR ... the population aged 50 years and above is afflicted by ... almost double by the year 2020. This has and will ...
(Date:8/29/2014)... Aug. 29, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" ... reported financial results for the six months ended ... expressed in Canadian dollars and presented under International ... 2014 Highlights , Announced top-line results ... primary endpoint for subjects enrolled in the Phase ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Three ... Energy's 2014 Hydrogen Production R&D Award ... by splitting water using sunlight. , Shared with ... and the University of Nevada, Las Vegas (UNLV), ... developing models of photoelectrochemical solar-hydrogen production and corrosion ...
Breaking Biology Technology:Breakthrough in light sources for new quantum technology 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4Livermore Team Awarded for Hydrogen Production Research 2
... INDIANAPOLIS, Sept. 23 The volume of biological samples ... pharmaceutical and biotechnology industries shift their focus from traditional ... and biomarkers in the discovery process has put an ... the practices that life sciences companies employ to collect, ...
... Pharmaceutical and Biotech Trainers (SPBT) today announced that Kevin ... October 1.  He brings to his new role significant ... Mr. Kruse will be responsible for leading ... organization that represents more than 1,000 members in the ...
... 23, 2010 ... ... var shortURL = ... so we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; ...
Cached Biology Technology:BioStorage Technologies Brings Together Industry Leaders for Global Sample Management Benchmarking Symposium 2BioStorage Technologies Brings Together Industry Leaders for Global Sample Management Benchmarking Symposium 3Kevin Kruse Named Executive Director of the Society of Pharmaceutical and Biotech Trainers 2BioSpain 2010 Will Host 2,000 Business Meetings in Which More Than 600 Companies Will Come Together 2BioSpain 2010 Will Host 2,000 Business Meetings in Which More Than 600 Companies Will Come Together 3BioSpain 2010 Will Host 2,000 Business Meetings in Which More Than 600 Companies Will Come Together 4BioSpain 2010 Will Host 2,000 Business Meetings in Which More Than 600 Companies Will Come Together 5BioSpain 2010 Will Host 2,000 Business Meetings in Which More Than 600 Companies Will Come Together 6BioSpain 2010 Will Host 2,000 Business Meetings in Which More Than 600 Companies Will Come Together 7
(Date:8/31/2014)... not busy attacking us, germs go after each other. ... disaster for the infected microbes: Sometimes viruses actually carry ... expand its diet or better attack its own hosts. ... immune system would robotically destroy anything it recognized as ... have now revealed that one variety of the bacterial ...
(Date:8/31/2014)... Climate Change , suggests that if current trends continue ... global targets for total greenhouse gas (GHG) emissions in 2050. ... carefully about the food we choose and its environmental impact. ... one of a number of actions that need to be ... enough food for all. , As populations rise and ...
(Date:8/31/2014)... in French . ... in the prestigious Nature Neuroscience journal by, Sylvain ... the Douglas Mental Health University Institute and McGill University, opens ... dynamic mechanisms controlling memory as well of the role of ... the subiculum. , In 2009, they developed a unique ...
Breaking Biology News(10 mins):Discovery reveals how bacteria distinguish harmful vs. helpful viruses 2Discovery reveals how bacteria distinguish harmful vs. helpful viruses 3Changing global diets is vital to reducing climate change 2Changing global diets is vital to reducing climate change 3Changing global diets is vital to reducing climate change 4Memory and Alzheimer's: Towards a better comprehension of the dynamic mechanisms 2
... genome-wide association study published today in Nature Genetics ... in eight blood measurements and the impact those variants ... the number and volume of cells in the blood, ... disorders, including anaemia, infection and blood cell cancers. ...
... of human papillomavirus is seen across the population of India, ... vaccination targeting these types could eliminate 75 percent of the ... the American Association for Cancer Research Frontiers in Basic Cancer ... the most common cancer among Indian women, with an estimated ...
... across the Panama Canal in a Boston Whaler may sound ... of this story brandishes a butterfly net and studies the ... Tropical Research Institute. , "Our long-term study shows ... migrations," said Robert Srygley, former Smithsonian post doctoral fellow who ...
Cached Biology News:Blood counts are clues to human disease 2Blood counts are clues to human disease 3Scientists identify common HPV genotypes in northern India, encourage vaccination 2Panama butterfly migrations linked to El Nio, climate change 2
Homo sapiens similar to Cytosolic acyl coenzyme A thioester hydrolase Antigen: Peptide...
96 Well Base Plate...
... Inhibitor is a potent noncompetitive ... as RNase A. Like other ... Inhibitor is an acidic protein ... kDa. RNaseOUT inhibits RNase A ...
... and Recombinant RNasin Ribonuclease Inhibitors have broad ... of eukaryotic RNases of the neutral type ... effect by noncovalently binding to RNases in ... the binding of RNasin Ribonuclease Inhibitor to ...
Biology Products: